Vidaza Alternatives Compared
| Vidaza (azacitidine) | Azacitidine | Reblozyl (luspatercept) |
|
|---|
| Vidaza (azacitidine) | Azacitidine | Reblozyl (luspatercept) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Myelodysplastic Syndrome. Vidaza may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myelodysplastic Syndrome, Acute Myeloid Leukemia. Azacitidine may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myelodysplastic Syndrome, Beta Thalassemia, Anemia. Reblozyl may also be used for purposes not listed in this medication guide. |
Related suggestions Myelodysplastic Syndrome
|
|||||||||||||||||||||||
| More about Vidaza (azacitidine) | More about Azacitidine | More about Reblozyl (luspatercept) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Vidaza has an average rating of 5.5 out of 10 from a total of 13 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 38% reported a negative effect. |
Azacitidine has an average rating of 5.9 out of 10 from a total of 19 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 32% reported a negative effect. |
Reblozyl has an average rating of 9.2 out of 10 from a total of 6 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Vidaza side effects |
View all Azacitidine side effects |
View all Reblozyl side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Vidaza prices |
View all Azacitidine prices |
View all Reblozyl prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other azacitidine brands include: Onureg | Onureg, Vidaza |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
0.82 hours |
0.82 hours |
264 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 178 drugs are known to interact with Vidaza:
|
A total of 178 drugs are known to interact with Azacitidine:
|
A total of 2 drugs are known to interact with Reblozyl:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
September 01, 2020 |
November 08, 2019 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Dacogen
Dacogen (decitabine) is used to treat myelodysplastic syndromes (certain types of blood or bone ...
Reblozyl
Reblozyl is used to treat anemia in adults with beta-thalassemia or myelodysplastic syndromes ...
Inqovi
Inqovi (decitabine and cedazuridine) is used for the treatment of myelodysplastic syndromes (MDS) ...
Rytelo
Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.